Omeros announces publication of narsoplimab survival benefits in TA-TMA

Omeros (OMER) announced the publication of a peer-reviewed manuscript in an American Society of Hematology journal, Blood Advances. The manuscript details survival outcomes in adult patients with transplant-associated thrombotic microangiopathy, or TA-TMA, treated with narsoplimab across both the pivotal clinical trial and the global expanded access program. The manuscript reports significant, multifold reductions in mortality risk across patient cohorts treated with narsoplimab compared to a well-matched external control group. Consistent with previous narsoplimab clinical studies, no safety signals of concern were observed. Narsoplimab is currently under review by the FDA and European Medicines Agency.